Deficiency of Both Farnesoid X Receptor and Takeda G Protein–Coupled Receptor 5 Exacerbated Liver Fibrosis in Mice

Jessica M. Ferrell, Preeti Pathak, Shannon Boehme, Tricia Gilliland, John Y. L. Chiang – 21 January 2019 – Activation of the nuclear bile acid receptor farnesoid X receptor (FXR) protects against hepatic inflammation and injury, while Takeda G protein–coupled receptor 5 (TGR5) promotes adipose tissue browning and energy metabolism. Here, we examined the physiological and metabolic effects of the deficiency of these two bile acid receptors on hepatic metabolism and injury in mice. Fxr/Tgr5 double knockout mice (DKO) were generated for metabolic phenotyping.

Identification of Polycystic Kidney Disease 1 Like 1 Gene Variants in Children With Biliary Atresia Splenic Malformation Syndrome

John‐Paul Berauer, Anya I. Mezina, David T. Okou, Aniko Sabo, Donna M. Muzny, Richard A. Gibbs, Madhuri R. Hegde, Pankaj Chopra, David J. Cutler, David H. Perlmutter, Laura N. Bull, Richard J. Thompson, Kathleen M. Loomes, Nancy B. Spinner, Ramakrishnan Rajagopalan, Stephen L. Guthery, Barry Moore, Mark Yandell, Sanjiv Harpavat, John C. Magee, Binita M. Kamath, Jean P. Molleston, Jorge A. Bezerra, Karen F. Murray, Estella M. Alonso, Philip Rosenthal, Robert H. Squires, Kasper S. Wang, Milton J. Finegold, Pierre Russo, Averell H. Sherker, Ronald J. Sokol, Saul J.

Direct Inhibition of Hepatitis B e Antigen by Core Protein Allosteric Modulator

Zhipeng Yan, Daitze Wu, Hui Hu, Jing Zeng, Xin Yu, Zhiheng Xu, Zheng Zhou, Xue Zhou, Guang Yang, John A.T. Young, Lu Gao – 21 January 2019 – Hepatitis B e antigen (HBeAg) is an important immunomodulator for promoting host immune tolerance during chronic hepatitis B (CHB) infection. In patients with CHB, HBeAg loss and seroconversion represent partial immune control of CHB infection and are regarded as valuable endpoints. However, the current approved treatments have only a limited efficacy in achieving HBeAg seroconversion in HBeAg‐positive patients.

The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis

Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Stephen Caldwell, Mitchell L. Shiffman, Charles Landis, Bertus Eksteen, Kosh Agarwal, Andrew Muir, Simon Rushbrook, Xiaomin Lu, Jun Xu, Jen‐Chieh Chuang, Andrew N. Billin, Georgia Li, Chuhan Chung, G. Mani Subramanian, Robert P. Myers, Christopher L. Bowlus, Kris V. Kowdley – 19 January 2019 – Primary sclerosing cholangitis (PSC) represents a major unmet medical need.

Lymphocyte Antigen 6 Complex, Locus C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice

Li‐Ling Wu, Wei‐Hao Peng, Hui‐Lin Wu, Shi‐Chuen Miaw, Shiou‐Hwei Yeh, Hung‐Chih Yang, Pei‐Hsuan Liao, Jing‐Shan Lin, Yan‐Rong Chen, Yen‐Tien Hong, Hurng‐Yi Wang, Pei‐Jer Chen, Ding‐Shinn Chen – 19 January 2019 – To understand the mechanism(s) of age‐dependent outcomes of hepatitis B virus (HBV) infection in humans, we previously established an age‐related HBV mouse model in which 6‐week‐old (N6W) C3H/HeN mice exhibited virus tolerance whereas 12‐week‐old (N12W) counterparts presented virus clearance.

Hepatology Highlights

Nicholas Russo, Arun Jesudian, Nicole T. Shen, Robert S. Brown, Akiko Sugiyama, Hayley T. Nicholls, Joseph F. Pisa, Tibor I. Krisko, Russell Rosenblatt, Zaid H. Tafesh, Brett E. Fortune, Omar Mousa, Harmeet Malhi, Robert E. Schwartz, Vikas Gupta, Tasha B. Kulai, Harmeet Malhi – 18 January 2019

Subscribe to